These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32077954)

  • 1. A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
    Mitra MS; Lancaster K; Adedeji AO; Palanisamy GS; Dave RA; Zhong F; Holdren MS; Turley SJ; Liang WC; Wu Y; Meng YG; Vernes JM; Schutten MM
    Toxicol Sci; 2020 May; 175(1):24-34. PubMed ID: 32077954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors.
    Welsh BT; Faucette R; Bilic S; Martin CJ; Schürpf T; Chen D; Nicholls S; Lansita J; Kalra A
    Int J Toxicol; 2021; 40(3):226-241. PubMed ID: 33739172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.
    Martin CJ; Datta A; Littlefield C; Kalra A; Chapron C; Wawersik S; Dagbay KB; Brueckner CT; Nikiforov A; Danehy FT; Streich FC; Boston C; Simpson A; Jackson JW; Lin S; Danek N; Faucette RR; Raman P; Capili AD; Buckler A; Carven GJ; Schürpf T
    Sci Transl Med; 2020 Mar; 12(536):. PubMed ID: 32213632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms.
    Bedinger D; Lao L; Khan S; Lee S; Takeuchi T; Mirza AM
    MAbs; 2016; 8(2):389-404. PubMed ID: 26563652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys.
    Loberg LI; Chhaya M; Ibraghimov A; Tarcsa E; Striebinger A; Popp A; Huang L; Oellien F; Barghorn S
    MAbs; 2021; 13(1):1887628. PubMed ID: 33596779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor.
    Gill M; Horn K; Hennan J; White R; Bounous D; Clark S; Megill JR; Janovitz E; Davies M; Sanderson T; Graziano M
    Toxicol Sci; 2017 Feb; 155(2):348-362. PubMed ID: 27864544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin.
    Beidler CB; Petrovan RJ; Conner EM; Boyles JS; Yang DD; Harlan SM; Chu S; Ellis B; Datta-Mannan A; Johnson RL; Stauber A; Witcher DR; Breyer MD; Heuer JG
    J Pharmacol Exp Ther; 2014 May; 349(2):330-43. PubMed ID: 24518034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis).
    Bowman CJ; Evans M; Cummings T; Oneda S; Butt M; Hurst S; Gremminger JL; Shelton D; Kamperschroer C; Zorbas M
    Reprod Toxicol; 2015 Jun; 53():105-18. PubMed ID: 25461901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.
    Gonzalez-Junca A; Reiners O; Borrero-Garcia LD; Beckford-Vera D; Lazar AA; Chou W; Braunstein S; VanBrocklin H; Franc BL; Barcellos-Hoff MH
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):527-539. PubMed ID: 33007434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody.
    Breslin WJ; Hilbish KG; Martin JA; Halstead CA; Newcomb DL; Chellman GJ
    Birth Defects Res B Dev Reprod Toxicol; 2015 Jun; 104(3):100-16. PubMed ID: 26195230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies.
    Adedeji AO; Zhong F; Getz JA; Zhong Z; Halpern W
    Toxicol Pathol; 2022 Dec; 50(8):910-919. PubMed ID: 36329562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
    Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
    Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments.
    Gropp KE; Carlson CS; Evans MG; Bagi CM; Reagan WJ; Hurst SI; Shelton DL; Zorbas MA
    Toxicol Pathol; 2018 Jun; 46(4):408-420. PubMed ID: 29768985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.
    Santostefano M; Herzyk D; Montgomery D; Wolf J
    Regul Toxicol Pharmacol; 2019 Nov; 108():104476. PubMed ID: 31536773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.
    Guha M; Thibault S; Pham S; Bernales S; Pai R; Herrera FJ; Johnson TR; Vitsky A; Fernando T; Finkelstein M
    J Pharmacol Exp Ther; 2024 Oct; 391(2):335-345. PubMed ID: 39284628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys.
    Rocca M; Han C; Butt M; Coogan TP
    Int J Toxicol; 2019; 38(3):173-182. PubMed ID: 30852923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFβ-Directed Therapeutics: 2020.
    Teicher BA
    Pharmacol Ther; 2021 Jan; 217():107666. PubMed ID: 32835827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.
    Pai R; Ma N; Connor AV; Danilenko DM; Tarrant JM; Salvail D; Wong L; Hartley DP; Misner D; Stefanich E; Wu Y; Chen Y; Wang H; Dambach DM
    Toxicol Sci; 2016 Jun; 151(2):245-60. PubMed ID: 26917699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.